Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 22;16(4):651.
doi: 10.3390/v16040651.

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

Selwyn J Hurwitz  1 , Ramyani De  1 , Julia C LeCher  1 , Jessica A Downs-Bowen  1 , Shu Ling Goh  1 , Keivan Zandi  1 , Tamara McBrayer  1 , Franck Amblard  1 , Dharmeshkumar Patel  1 , James J Kohler  1 , Manoj Bhasin  2 , Brian S Dobosh  2 , Vikas Sukhatme  3 , Rabindra M Tirouvanziam  2 , Raymond F Schinazi  1
Affiliations

Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections

Selwyn J Hurwitz et al. Viruses. .

Abstract

Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical trials, in Vero cells. Ratios of reported unbound peak plasma concentrations, (Cmax)/EC50, were used to predict the potential in vivo efficacy. The 20 drugs with the highest ratios were retested in human Calu-3 and Caco-2 cells, and their CC50 was determined in an expanded panel of cell lines. Many of the 20 drugs with the highest ratios were inactive in human Calu-3 and Caco-2 cells. Antivirals effective in controlled clinical trials had unbound Cmax/EC50 ≥ 6.8 in Calu-3 or Caco-2 cells. EC50 of nucleoside analogs were cell dependent. This approach and earlier availability of more relevant cultures could have reduced the number of unwarranted clinical trials.

Keywords: COVID-19; SARS-CoV-2; antiviral agents; coronavirus; drug repurposing; pharmacokinetics; potency; potential efficacy.

PubMed Disclaimer

Conflict of interest statement

R.F.S. has received royalties from Ely Lilly from the sales of baricitinib, used for the treatment of COVID-19. RFS received research funding from Pfizer for his group at Emory University. Emory University has reviewed and approved his conflict of interest. Other authors have no conflicts of interest to declare regarding this manuscript.

References

    1. U.S. Centers for Disease Control and Prevention Overview of COVID-19 Vaccines. [(accessed on 28 November 2023)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/ov....
    1. Yap C., Ali A., Prabhakar A., Prabhakar A., Pal A., Lim Y.Y., Kakodkar P. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther. Adv. Vaccines Immunother. 2021;9:25151355211059791. doi: 10.1177/25151355211059791. - DOI - PMC - PubMed
    1. Fan Y.J., Chan K.H., Hung I.F. Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of different vaccines at phase 3. Vaccines. 2021;9:989. doi: 10.3390/vaccines9090989. - DOI - PMC - PubMed
    1. Narayanan A., Narwal M., Majowicz S.A., Varricchio C., Toner S.A., Ballatore C., Brancale A., Murakami K.S., Jose J. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun. Biol. 2022;5:169. doi: 10.1038/s42003-022-03090-9. - DOI - PMC - PubMed
    1. Malin J.J., Suarez I., Priesner V., Fatkenheuer G., Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 2020;34:e00162-20. doi: 10.1128/CMR.00162-20. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources